Kids & teens (for parents) · California
Studies for children and teens in California
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
149 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Crinetics Pharmaceuticals Inc.
- Location
- San Francisco, CA + 9 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Pfizer
- Location
- Orange, CA + 10 other US sites
- Eligibility basics
- Up to age 10 mo
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Irvine, CA + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Anaheim, CA + 12 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Paradigm Therapeutics
- Location
- Rancho Santa Margarita, CA + 3 other US sites
- Eligibility basics
- Ages 1 mo–12
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Hawthorne, CA + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation
- Location
- Palo Alto, CA + 10 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
AstraZeneca
- Location
- Long Beach, CA + 18 other US sites
- Eligibility basics
- Ages 5–11
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Palo Alto, CA + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Long Beach, CA + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Loma Linda, CA + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Los Angeles, CA + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 2
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
AstraZeneca
- Location
- Bakersfield, CA + 11 other US sites
- Eligibility basics
- Ages 4–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Anaheim, CA + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Anaheim, CA + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Eli Lilly and Company
- Location
- Oxnard, CA
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Anaheim, CA + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Incyte Corporation
- Location
- Duarte, CA + 6 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- Stanford, CA + 10 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Ionis Pharmaceuticals, Inc.
- Location
- San Francisco, CA + 4 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Anaheim, CA + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Loma Linda, CA + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Anaheim, CA + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Anaheim, CA + 12 other US sites
- Eligibility basics
- Ages 13–17